ESPR Esperion Therapeutics, Inc.
Healthcare$3.12-0.32%ClosedMarket Cap: $648.7M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
-2.55
P/S
1.56
EV/EBITDA
9.68
DCF Value
$-67.92
FCF Yield
-2.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
65.0%
Operating Margin
18.1%
Net Margin
-1.8%
ROE
2.0%
ROA
-1.6%
ROIC
46.2%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $80.1M | 56.8% | $-6.6M | $-25.2M | $— | — |
| Q4 null | $168.4M | 83.5% | $85.2M | $61.8M | $— | — |
| FY null | $403.1M | 67.9% | $60.3M | $-22.7M | $— | — |
| Q3 null | $87.3M | 36.5% | $-10.0M | $-31.3M | $— | — |
| Q2 null | $82.4M | 65.4% | $7.1M | $-12.7M | $— | — |
| Q1 null | $65.0M | 51.5% | $-22.1M | $-40.5M | $— | — |
| Q4 null | $69.1M | 62.9% | $-4.4M | $-21.3M | $— | — |
| FY null | $332.3M | 79.4% | $54.4M | $-51.7M | $— | — |
| Q3 null | $51.6M | 66.5% | $-16.0M | $-29.5M | $— | — |
| Q2 null | $73.8M | 78.9% | $2.6M | $-61.9M | $— | — |
| Q1 null | $137.7M | 92.7% | $72.3M | $61.0M | $— | — |
| Q4 2023 | $32.3M | 64.5% | $-42.4M | $-56.3M | $-0.50 | — |